The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC

J Thorac Oncol. 2018 Aug;13(8):1058-1059. doi: 10.1016/j.jtho.2018.06.003. Epub 2018 Jul 2.

Authors

Aaron Lisberg¹, Edward B Garon²

Affiliations

¹ David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
² David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California. Electronic address: egaron@mednet.ucla.edu.

PMID: 30056858
DOI: 10.1016/j.jtho.2018.06.003

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
ErbB Receptors
Humans
Italy
Lung Neoplasms*
Nivolumab
Programmed Cell Death 1 Receptor
Smokers
Smoking

Substances

Programmed Cell Death 1 Receptor
Nivolumab
EGFR protein, human
ErbB Receptors